Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Ropidoxuridine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2017.